Member Info for cossie

Provide a link to the so called Telegram group. If you search telegram @neo there are no such groups. Back up your findings rather than appearing to deramp. Also explain new subscription for shares at a premium of 1.25p, red flag here then?

ii settled today electronically into nominee accounts. HL seem to take an age. Keeping mine Q4 is going to be good for CGO

Thanks for the confirmation Paladin. I have just checked my ii account and my CGO shares are now available to trade. I did a dummy sell and got a firm price. At long last it has finally happened. BTW I am holding CGO and probably add to the position .ATB

Hi Jimtom, have you contacted HL. I think the guys with nominee accounts could see there shareholding but it was showing nil value. If you can see a value against yours, i would say you are further down the line. Maybe worth a secure message or call. I am with ii and can see nothing as yet. If they are issuing physical share certificates, even to those with nominee account holdings then this will take some time. There are over 700 registered CGH shares holders due CGO shares.

It is not come through on ii. The flag is regarding the initial corporate action. There has been no further updates in ii.

Good to keep reaching out, but with 700 shareholders in CGH is will take a bit of time.

from 8th July RNS
"Physical share certificates will be issued to the registered addresses of all CGH investors over the coming weeks"

Nothing in my ii account either. I would expect they will transferred across all accounts at the same time so not to give any unfair advantage if you wanted to deal

ii have already issued the corporate action notification

A friend has just got the corporate action from Charles Stanley that they have received the CGO notification.

that is correct, Avenir are registrars for Contango and will prepare and issue new share certificates to all qualifying CGH shareholders.

Got my notification from ii too. Good news!

Can anyone share the letter so I can forward it to interactive investor? thanks

I have written to Interactive Investor attaching the recent correspondence. Let's see what they have to say. ATB

Worrying thing is this letter never reached any of the CGH shareholders. Just hidden away in a drop box!

Where are these letters being sent to? If at all? Why can they not just pro-rata CGO shares instead of this dividend ?

https://www.dropbox.com/sh/vca479ckc5m57mr/AAC2YozLlykY9xSuwl9dKi6va?dl=0

17 March 2022

Scancell Holdings plc

("Scancell" or the "Company")

Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab(TM)

Initial anti-glycan mAbs from the GlyMab(TM) platform have now been successfully humanised

Fourth research agreement on Glymab(TM) platform signed with major European Pharma

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides an update on its anti-glycan monoclonal antibody (mAb) platform, now branded GlyMab(TM). The Company's fourth proprietary platform has the potential to expand further its pipeline of novel anti-cancer mAbs and the versatility to yield other drug formats including antibody drug conjugate and CAR-T candidates. Scancell is developing a unique pipeline of tumour-specific anti-glycan antibodies with the initial aim of generating early-stage clinical data, either alone or in combination with potential strategic partners.

The Company currently has a pipeline of five anti-glycan mAbs: SC129, SC134, SC88 and SC27 that target solid tumours including pancreatic, small cell lung, colorectal and gastric, and SC2811 that targets a glycolipid on T cell stem cells. Four (SC129, SC27, SC134 and SC88) out of five of these drug candidates have now been successfully humanised and are therefore ready for the next stage of development.

In addition, the company is pleased to announce its fourth research collaboration agreement based on the Glymab(TM) platform. The agreement is with a major European pharmaceutical company and is designed to further evaluate one of the company's Glymab(TM) antibodies for the treatment of cancer.

Scancell believes that GlyMab(TM) can be employed to produce additional differentiated anti-cancer mAbs that target sugar motifs (glycans) present on putative lipid and / or protein drug targets. The platform also has the potential to be used for drug delivery as antibody drug conjugates (ADCs), as chimeric antigen receptor (CAR) T cells or for redirected T cell killing. Furthermore, such high affinity anti-glycan mAbs also have the potential to be used for targeted imaging to distinguish malignant from healthy tissue during cancer surgery.(1,2)

A robust portfolio of patents and applications, as well as know-how, surround the GlyMab(TM) platform and generated drug candidates. The GlyMab(TM) technology is part of Scancell's antibody portfolio, joining AvidiMab(R) , a technology that can be applied to all antibodies (regardless of the technology used to generate them), enhancing their potency and ability to directly kill tumour cells.

Prof Lindy Durrant, Chief Executive Officer, Scancell, commented:

"We believe our proprietary GlyMab(TM) platform provides a powerful and versatile approach to generating novel antibody drug candidates that bind to sugar motifs, rather than peptide epitopes, found on the surface of glycosylated proteins and lipids that are implica

for example from Redmile Growth Fund to a Redmile Special Fund . Price neutral transfer.

from Telegram Group: "The big trade was just an internal fund realignment"

register with https://www.investormeetcompany.com/

The Company is progressing multiple commercial opportunities with distributors and end users in Europe and this product registration is the key final step towards commercialisation.